Founded in 2000, Latterell Venture Partners invests exclusively in early stage healthcare companies, including biotechnology, pharmaceutical, research instrument, biomaterial, medical device, healthcare IT, and diagnostic ventures. These ventures should research and develop products that treat major diseases and medical disorders.

The differentiating feature of LVP is the unique blend of technical, clinical, operational, entrepreneurial and venture capital skills of our partners. LVP's team consists of two seasoned venture capitalists from Venrock and Sprout/Merrill Lynch, a leading clinician engineer from Stanford Medical School, a former senior R&D executive from Roche Pharmaceuticals and Centocor, a successful medical device entrepreneur and senior R&D executive from Boston Scientific, and a former biopharmaceutical entrepreneur and CEO from Molecular Biosystems.

Latterell's initial investments range from $50,000 to $10 million, depending on the stage of development of a technology or product. Latterell plans to support portfolio companies beyond the initial investment through subsequent private equity financings, with an expectation to invest $10-$20 million in each portfolio company.

Notable investments include: Calistoga Pharmaceuticals (acquired by Gilead Sciences), CellBiosciences (acquired by Bio-Techne), Neutraltus Pharmaceuticals, OncoMed Pharmaceuticals (NASDAQ: OMED), Pathway Medical Technologies (acquired by MEDRAD), PerceptiMed, PulmonX, ReVascular Therapeutics and TetraLogic Pharmaceuticals (NADSAQ: TLOG).